115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
    Meeting Abstract

    Vieito, M.; McKean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Garcia, V. M.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC)
    Meeting Abstract

    George, M.; Frenel, J. S.; CorteĢs, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Weller, M.; Berry, D. A.; Blondin, N.; Buxton, M.; Colman, H.; de Groot, J. F.; de la Fuente, M.; Ducray, F.; Ellingson, B.; Gordon, G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
    Meeting Abstract

    Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2e breast cancer (BC)
    Meeting Abstract

    Rugo, H. S.; Bardia, A.; Im, S. A.; Simon, S. P.; De Laurentiis, M.; Wang, S.; Martinez, N.; Borges, G. S.; Cescon, D.; Hattori, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Meeting Abstract

    Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Losada, M. J. V.; Park, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
    Meeting Abstract

    Modi, S.; Byng, D.; Zhang, S.; Xiong, Y.; Hunter, S.; Struebing, A.; Dunton, K.; Mbanya, Z.; Jacot, W.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
    Meeting Abstract

    Cabel, L.; An, J. A. R.; Kurtz, D.; Ross, D.; Dikoglu, E.; Chen, Y.; Murphy, K.; Szuhany, K.; Stowell, S. L.; Maloney, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2-early breast cancer (EBC) from US electronic health records (EHR)
    Meeting Abstract

    Jhaveri, K.; Pegram, M.; Neven, P.; Curigliano, G.; Spring, L. M.; Gligorov, J.; Schlam, I.; Harbeck, N.; Juric, D.; Lim, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save